Cullinan Oncology, Inc. (NASDAQ:CGEM – Get Rating) major shareholder Bioscience I. 2017 Ltd F2 sold 29,631 shares of Cullinan Oncology stock in a transaction dated Thursday, June 23rd. The stock was sold at an average price of $13.00, for a total value of $385,203.00. Following the completion of the sale, the insider now owns 537,392 shares in the company, valued at $6,986,096. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.
CGEM stock traded up $0.59 during trading on Thursday, hitting $13.32. The stock had a trading volume of 288,158 shares, compared to its average volume of 401,262. Cullinan Oncology, Inc. has a twelve month low of $7.30 and a twelve month high of $30.33. The stock has a market capitalization of $596.51 million, a P/E ratio of -7.53 and a beta of 0.17. The company’s 50-day moving average price is $11.14 and its two-hundred day moving average price is $12.93.
Cullinan Oncology (NASDAQ:CGEM – Get Rating) last issued its earnings results on Monday, May 16th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.34. As a group, equities analysts anticipate that Cullinan Oncology, Inc. will post 3.39 earnings per share for the current fiscal year.
Separately, HC Wainwright reiterated a “buy” rating and issued a $50.00 price objective on shares of Cullinan Oncology in a report on Tuesday, May 17th.
About Cullinan Oncology (Get Rating)
Cullinan Oncology Inc, a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer.
- Get a free copy of the StockNews.com research report on Cullinan Oncology (CGEM)
- It’s A Comfortable Time To Buy Steelcase
- Worthington Posts Strong Results, But Earnings Fall On One-Off Adjustments
- A Tasty Entry Point Into Darden Restaurants International
- NXP Semiconductors: Strong Earnings & New Microcontrollers for Electric Vehicles
- Lithium Stocks Are Offering Unprecedented Opportunity To Investors
Receive News & Ratings for Cullinan Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Oncology and related companies with MarketBeat.com's FREE daily email newsletter.